Common Stock, par value $0.01 per share
- Symbol
- IMNN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Imunon, Inc.
IMNNNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 26, 2026, Imunon, Inc. (the “Company”) made available an investor presentation (the “Investor Presentation”), which the Company expects to use in connection with investor calls and/or conferences. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Company context
Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.
Current securities
Registered securities in this filing
Imunon, Inc. · 8-K · Filed 2026-10-27
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
October 26, 2026, Imunon, Inc. (the “Company”) made available an investor presentation (the “Investor Presentation”),
which the Company expects to use in connection with investor calls and/or conferences. A copy of the Investor Presentation is attached
hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1
Open exhibit ↗